Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($5.40), $3.75 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $107.02 million versus the consensus estimate of $102.69 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.